Targeting the Hippo Pathway and Cancer Through the TEAD Family of Transcription Factors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Mar 21

PMID 29558384

Citations 92

Authors

Jeffrey K Holden

Christian N Cunningham

Affiliations

Soon will be listed here.

Abstract

The Hippo pathway is a critical transcriptional signaling pathway that regulates cell growth, proliferation and organ development. The transcriptional enhanced associate domain (TEAD) protein family consists of four paralogous transcription factors that function to modulate gene expression in response to the Hippo signaling pathway. Transcriptional activation of these proteins occurs upon binding to the co-activator YAP/TAZ whose entry into the nucleus is regulated by Lats1/2 kinase. In recent years, it has become apparent that the dysregulation and/or overexpression of Hippo pathway effectors is implicated in a wide range of cancers, including prostate, gastric and liver cancer. A large body of work has been dedicated to understanding the therapeutic potential of modulating the phosphorylation and localization of YAP/TAZ. However, YAP/TAZ are considered to be natively unfolded and may be intractable as drug targets. Therefore, TEAD proteins present themselves as an excellent therapeutic target for intervention of the Hippo pathway. This review summarizes the functional role of TEAD proteins in cancer and assesses the therapeutic potential of antagonizing TEAD function in vivo.

Citing Articles

Transcriptomic effects of alginate hydrogel applied to the production of bovine embryos.

Ferronato G, Rosa P, Bridi A, Dos Santos A, Nociti R, Chiaratti M Heliyon. 2025; 10(24):e40957.

PMID: 39759294 PMC: 11700250. DOI: 10.1016/j.heliyon.2024.e40957.

Research progress of the Hippo signaling pathway in renal cell carcinoma.

Yang Y, Gan X, Zhang W, Zhu B, Huangfu Z, Shi X Asian J Urol. 2024; 11(4):511-520.

PMID: 39534002 PMC: 11551326. DOI: 10.1016/j.ajur.2024.02.005.

TEAD transcription factor family emerges as a promising therapeutic target for oral squamous cell carcinoma.

Wang S, Shao D, Gao X, Zhao P, Kong F, Deng J Front Immunol. 2024; 15:1480701.

PMID: 39430767 PMC: 11486717. DOI: 10.3389/fimmu.2024.1480701.

Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo.

Zhu R, Liu X, Zhang X, Zhong Z, Qi S, Jin R Cell Rep Med. 2024; 5(10):101763.

PMID: 39368484 PMC: 11513813. DOI: 10.1016/j.xcrm.2024.101763.

Mammalian START-like phosphatidylinositol transfer proteins - Physiological perspectives and roles in cancer biology.

Pathak A, Willis K, Bankaitis V, McDermott M Biochim Biophys Acta Mol Cell Biol Lipids. 2024; 1869(7):159529.

PMID: 38945251 PMC: 11533902. DOI: 10.1016/j.bbalip.2024.159529.

References

Sievers F, Wilm A, Dineen D, Gibson T, Karplus K, Li W . Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011; 7:539. PMC: 3261699. DOI: 10.1038/msb.2011.75. View

Cairns L, Tran T, Kavran J . Structural Insights into the Regulation of Hippo Signaling. ACS Chem Biol. 2017; 12(3):601-610. DOI: 10.1021/acschembio.6b01058. View

Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H . Structural insights into the YAP and TEAD complex. Genes Dev. 2010; 24(3):235-40. PMC: 2811825. DOI: 10.1101/gad.1865810. View

Galli G, Carrara M, Yuan W, Valdes-Quezada C, Gurung B, Pepe-Mooney B . YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. Mol Cell. 2015; 60(2):328-37. PMC: 4624327. DOI: 10.1016/j.molcel.2015.09.001. View

Feichtinger M, Sara T, Platzer G, Mateos B, Bokhovchuk F, Chene P . H, C, N resonance assignment of human YAP 50-171 fragment. Biomol NMR Assign. 2018; 12(1):179-182. PMC: 5869869. DOI: 10.1007/s12104-018-9805-8. View

Kaneko K, DePamphilis M . Regulation of gene expression at the beginning of mammalian development and the TEAD family of transcription factors. Dev Genet. 1998; 22(1):43-55. DOI: 10.1002/(SICI)1520-6408(1998)22:1<43::AID-DVG5>3.0.CO;2-7. View

Tian W, Yu J, Tomchick D, Pan D, Luo X . Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci U S A. 2010; 107(16):7293-8. PMC: 2867681. DOI: 10.1073/pnas.1000293107. View

Gibault F, Sturbaut M, Bailly F, Melnyk P, Cotelle P . Targeting Transcriptional Enhanced Associate Domains (TEADs). J Med Chem. 2017; 61(12):5057-5072. DOI: 10.1021/acs.jmedchem.7b00879. View

Pobbati A, Han X, Hung A, Weiguang S, Huda N, Chen G . Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure. 2015; 23(11):2076-86. PMC: 4660270. DOI: 10.1016/j.str.2015.09.009. View

10.

Halder G, Polaczyk P, Kraus M, Hudson A, Kim J, Laughon A . The Vestigial and Scalloped proteins act together to directly regulate wing-specific gene expression in Drosophila. Genes Dev. 1998; 12(24):3900-9. PMC: 317267. DOI: 10.1101/gad.12.24.3900. View

11.

Mesrouze Y, Meyerhofer M, Bokhovchuk F, Fontana P, Zimmermann C, Martin T . Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ. Protein Sci. 2017; 26(12):2399-2409. PMC: 5699492. DOI: 10.1002/pro.3312. View

12.

Skotheim R, Autio R, Lind G, Kraggerud S, Andrews P, Monni O . Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Cell Oncol. 2006; 28(5-6):315-26. PMC: 4615958. DOI: 10.1155/2006/219786. View

13.

Chan P, Han X, Zheng B, DeRan M, Yu J, Jarugumilli G . Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat Chem Biol. 2016; 12(4):282-9. PMC: 4798901. DOI: 10.1038/nchembio.2036. View

14.

Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B . Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015; 17(9):1218-27. PMC: 6186417. DOI: 10.1038/ncb3216. View

15.

Kaneko K, Kohn M, Liu C, DePamphilis M . Transcription factor TEAD2 is involved in neural tube closure. Genesis. 2007; 45(9):577-87. PMC: 2765819. DOI: 10.1002/dvg.20330. View

16.

Liu-Chittenden Y, Huang B, Shim J, Chen Q, Lee S, Anders R . Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012; 26(12):1300-5. PMC: 3387657. DOI: 10.1101/gad.192856.112. View

17.

Noland C, Gierke S, Schnier P, Murray J, Sandoval W, Sagolla M . Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling. Structure. 2016; 24(1):179-186. DOI: 10.1016/j.str.2015.11.005. View

18.

Sagendorf J, Berman H, Rohs R . DNAproDB: an interactive tool for structural analysis of DNA-protein complexes. Nucleic Acids Res. 2017; 45(W1):W89-W97. PMC: 5570235. DOI: 10.1093/nar/gkx272. View

19.

Knight J, Shepherd C, Rizzo S, Brewer D, Jhavar S, Dodson A . TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer. 2008; 99(11):1849-58. PMC: 2600693. DOI: 10.1038/sj.bjc.6604774. View

20.

Ren Y, Chaerkady R, Hu S, Wan J, Qian J, Zhu H . Unbiased discovery of interactions at a control locus driving expression of the cancer-specific therapeutic and diagnostic target, mesothelin. J Proteome Res. 2012; 11(11):5301-10. PMC: 3761944. DOI: 10.1021/pr300797v. View